Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Subscribe To Our Newsletter & Stay Updated